Chairman of the Porton Biopharma (PBL) Martin Hindle opened an extension of its facility for the storage of raw materials.
PBL manufactures a number of key bio-pharmaceutical products, including Erwinase®. The drug is principally used to cure childhood leukaemia around the world.
The company was commercialised out of Public Health England earlier this year to enable it to have more operational freedom, which includes the ability to invest in key facilities.
Mr Hindle said "This new extension is the first physical demonstration of the belief we all have in the company and our vision for the future.
By building up our capacity it will enable us to grow the business, securing the future for our staff, and providing more life-saving products."
The £1.3m extension adds an additional 168m2 for goods receipt and booking-in, as well as quarantine storage to the existing building.
This unit handles all incoming raw materials and disposables to enable them to be checked and approved for use in the highly regulated pharmaceutical manufacturing plants on site.
In addition to the extension, there is an improved access ramp and additional external, corrosive, and flammable stores.